Incyte v. Concert Pharma: Dismissed Appeal in Deuterated JAK Inhibitor Patent Case

The Court of Appeals for the Federal Circuit dismissed Case No. 23-1300, Incyte Corporation v. Concert Pharmaceuticals, Inc., on May 7, 2025 — closing an 861-day appellate proceeding centered on patent invalidity and cancellation claims tied to deuterated JAK inhibitor technology for treating hair loss disorders.

At issue was U.S. Patent No. US10561659B2, covering the use of deuterium-modified JAK (Janus kinase) inhibitors in hair loss disorder treatment — a commercially significant therapeutic category that has drawn intense IP competition as biologic and small-molecule alopecia treatments gain FDA traction.

The dismissal, ordered without a substantive ruling on patentability merits, raises immediate questions for patent attorneys monitoring pharmaceutical IP strategy, in-house counsel tracking competitive positioning in the dermatology space, and R&D teams evaluating freedom-to-operate in the growing JAK inhibitor pipeline.

This case analysis examines the procedural history, legal context, and strategic implications of the Federal Circuit’s dismissal for pharmaceutical patent litigation stakeholders.

Case Overview

The Parties

The Patent at Issue

This landmark case involved U.S. Patent No. US10561659B2 (Application No. US16/098338) covering treatment of hair loss disorders using deuterated JAK inhibitors.

Deuterium-modified compounds represent a distinct and legally complex IP category, as their novelty over non-deuterated predecessors has been an active area of patentability debate at the USPTO and in federal courts.

The Accused Technology

The product category at the center of this dispute — deuterated JAK inhibitors for hair loss — sits at the intersection of two high-value pharmaceutical trends: the expansion of JAK inhibitor indications and deuterium-based drug differentiation strategies.

Legal Representation

Incyte was represented by Finnegan, Henderson, Farabow, Garrett & Dunner, LLP, one of the country’s premier patent litigation firms. Attorneys of record included Drew Christie, J. Derek McCorquindale, Jason Lee Romrell, and Mark J. Feldstein. Defendant agent and law firm information was not available in the case record.

Litigation Timeline & Procedural History

The appeal was filed in the District of Columbia jurisdiction on December 28, 2022, before the Federal Circuit — the exclusive appellate venue for U.S. patent matters. The Federal Circuit’s specialized jurisdiction over patent appeals makes its rulings particularly significant for establishing or reinforcing claim construction standards, patentability doctrine, and procedural norms applicable nationwide.

The 861-day duration reflects a timeline consistent with complex pharmaceutical patent appeals, which frequently involve multi-round briefing, amicus participation, and scheduling accommodations for technically dense subject matter. The case ultimately closed with dismissal rather than a merits ruling, suggesting procedural resolution — potentially mooted by an underlying development — rather than substantive adjudication.

Specific intermediate milestones, including oral argument dates or panel composition, were not available in the provided case record.

The Verdict & Legal Analysis

Outcome

The Federal Circuit issued the following order:

“THIS CAUSE having been considered, it is ORDERED AND ADJUDGED: DISMISSED.”

The case was terminated on the basis of dismissal. No damages award was entered, no injunctive relief was granted or denied on the merits, and no substantive ruling on patent validity or claim construction was issued. The specific procedural basis for termination was not disclosed in the available case data.

Verdict Cause Analysis

The stated verdict cause was Patentability, categorized under an Invalidity/Cancellation Action. This framing indicates Incyte was likely challenging the validity or continued enforceability of Concert’s US10561659B2 — either through an appeal from a PTAB inter partes review (IPR) proceeding or through direct appellate challenge to a district court patentability ruling.

Deuterated compound patents occupy a contested zone in patentability analysis. The USPTO and federal courts have grappled with whether deuterium substitution, standing alone, constitutes a non-obvious modification of a known compound — particularly when the pharmacological activity is well-understood. Key legal doctrines at play in such disputes include:

• Obviousness (35 U.S.C. § 103): Courts and the PTAB have split on whether deuterium modification of a known JAK inhibitor scaffold presents sufficient unexpected results to overcome obviousness rejections grounded in prior art disclosures of the base compound.
• Enablement and Written Description (35 U.S.C. § 112): Broad claims covering classes of deuterated analogs may face challenges over whether the specification adequately supports the full claim scope.
• Claim Construction: The specific placement and degree of deuterium substitution claimed in US10561659B2 would be central to any infringement or validity analysis.

Without a merits ruling, the Federal Circuit provided no precedential guidance on these doctrines in this instance.

Legal Significance

A dismissal without substantive ruling carries limited direct precedential value. However, the underlying patentability challenge to deuterated JAK inhibitor claims remains live as a legal question across the industry. The dismissal leaves US10561659B2’s validity status determined by whatever lower-level proceeding preceded this appeal — and that determination (or lack thereof) governs Concert’s (now AbbVie’s, following acquisition) IP rights in this space.

Strategic Takeaways

For Patent Holders:

Dismissal of a validity challenge — regardless of reason — functionally preserves the challenged patent’s enforceability unless the underlying proceeding resulted in cancellation. Patent holders facing serial validity attacks should monitor whether dismissal at the appellate level reflects a strategic withdrawal by the challenger, a settlement, or mootness due to business events.

For Accused Infringers and Challengers:

Filing invalidity or cancellation actions against deuterated compound patents requires careful evaluation of whether the challenge vehicle (IPR, district court, or appellate review) aligns with business timelines. An 861-day appeal that ends in dismissal — without invalidating the target patent — represents a significant resource expenditure without the intended IP clearance.

For R&D Teams:

Companies developing deuterated analogs of JAK inhibitors, or working in the alopecia areata treatment space, should conduct updated freedom-to-operate analyses accounting for US10561659B2’s continued existence and the unresolved patentability questions this case leaves open.

Industry & Competitive Implications

The pharmaceutical landscape for JAK inhibitors in dermatology has transformed dramatically since this appeal was filed. Oral and topical JAK inhibitors — including baricitinib and ruxolitinib — have received FDA approvals for alopecia areata, creating a commercially validated market that amplifies the competitive significance of any IP position in this space.

Concert Pharmaceuticals was acquired by AbbVie in 2023, significantly altering the competitive dynamics and strategic resource calculus underpinning this litigation. The dismissal may reflect, at least in part, the practical consequences of that corporate transition — including reassessment of litigation posture by new ownership.

For companies operating in the deuterium drug space broadly — including those developing deuterated analogs of other kinase inhibitors — this case underscores that patent validity challenges against deuterated compound claims remain unresolved legal territory. The absence of a Federal Circuit merits ruling means practitioners cannot draw on this case for obviousness or enablement guidance.

Licensing strategies in this sector should account for the continued uncertainty: deuterated JAK inhibitor patents may be strong IP assets or vulnerable claims depending on claim-specific analysis — a distinction this dismissal does not resolve.

FAQ